Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 13:8:659292.
doi: 10.3389/fsurg.2021.659292. eCollection 2021.

Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer-A Pilot Study

C A Chai  1 , W S Yeoh  1 , R Rajandram  1 , K P Aung  1 , T A Ong  1 , S Kuppusamy  1 , A Nazran  1 , K Kumaran  1 , A H A Razack  1 , J Y Teoh  2
Affiliations

Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer-A Pilot Study

C A Chai et al. Front Surg. .

Abstract

Purpose: Guidelines advocate cystoscopy surveillance (CS) for non-muscle invasive bladder cancer (NMIBC) post-resection. However, cystoscopy is operator dependent and may miss upper tract lesions or carcinoma in-situ (CIS). Urine cytology is a common adjunct but lacks sensitivity and specificity in detecting recurrence. A new mRNA biomarker (CxBladder) was compared with urine cytology as an adjunct to cystoscopy in detecting a positive cystoscopy findings during surveillance cystoscopy in our center. Materials and Methods: Consented patients older than 18, undergoing CS for NMIBC, provide paired urine samples for cytology and CxBladder test. Patients with positive cystoscopy findings would undergo re-Trans Urethral Resection of Bladder Tumor (TURBT). Results: Thirty-five patients were enrolled from April to June 2019. Seven contaminated urine samples were excluded. The remaining cohort of 23 (82%) and 5 (18%) females had a mean age of 66.69 (36-89). Eight (29%) patients with positive cystoscopy finding underwent TURBT. All 8 patients also had positive CxBladder result. This shows that CxBladder has a sensitivity and negative predictive value (NPV) of 100%, specificity of 75% and positive predictive value (PPV) of 62% in predicting a positive cystoscopy finding. TURBT Histo-pathological findings showed Low-grade Ta NMIBC in one patient (4%), and 7 (25%) patients had inflammatory changes. Urine cytology was only positive in one patient with a positive cystoscopy finding. This led to a sensitivity of merely 13% and NPV of 74%, while specificity and PPV was 100% in predicting a positive cystoscopy finding. Conclusion: CxBladder had high NPV and sensitivity which accurately predicted suspicious cystoscopy findings leading to further investigation. It has great potential for use as adjunct to cystoscopy for surveillance of NMIBC.

Keywords: CxBladder; bladder cancer; cystoscopy; non-muscle invasive bladder cancer; urine cytology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Consort diagram of the selection criteria of bladder cancer cases.
See this image and copyright information in PMC

References

    1. Gianluca G, Crestani A, Vincenzo F. Re: robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non inferiority trial. Eur Urol. (2019) 71:618–29. 10.1016/j.Eururo.2018.08.003 - DOI - PubMed
    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. . GLOBOCAN 2012 v1.0: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available online at: http://publications.iarc.for/Databases/Iarc-cancerbases/GLOBOCAN-2012-Es...
    1. Comperat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, et al. . Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. (2015) 466:589. 10.1007/s00428-015-1739-2 - DOI - PubMed
    1. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. (2006) 49:466. 10.1016/j.eururo.2005.12.031 - DOI - PubMed
    1. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. . Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. (2016) 196:1021–9. 10.1016/j.juro.2016.06.049 - DOI - PubMed

LinkOut - more resources